InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Stark declines to enhance Idenix’s record $2.5bn patent damages award

Michael Loney, New York


District of Delaware says additional sanction is not warranted in Idenix v Gilead “given that the result of that misconduct is a cure for a potentially-fatal disease afflicting millions of people around the world, and given that the jury's damages award is already the largest damages verdict ever returned in a patent trial”

The District of Delaware has denied Idenix’s request to enhance the damages of $2.54 it was awarded for Gilead infringing its patents related to Hepatitis C drugs, which was the largest ever patent damages award in the US. Idenix was...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

RT @UPCtracker: This is one of nine (9) cases allocated to Justice Prof Huber (among them consolidated complaint re: adequate legal protect…

Feb 21 2018 05:15 ·  reply ·  retweet ·  favourite
ManagingIP profile

The complaint against the legislation enabling Germany to ratify the Agreement on a Unified Patent Court is includ… https://t.co/91NMMhmuYn

Feb 21 2018 05:15 ·  reply ·  retweet ·  favourite
ManagingIP profile

Pfizer argued that plausibility should be an "evidential tool" not a "threshold test", while Actavis warned against… https://t.co/EqhdqxmE6J

Feb 21 2018 05:09 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

February 2018

FRAND aid: Is the European Commission’s SEP guidance useful?

Both patent owners and implementers have welcomed the European Commission’s communication on standard essential patents. Does that mean it has successfully balanced competing interests or merely dodged the difficult questions? James Nurton investigates



Most read articles

Supplements